Skip to content

ADMA Biologics ADMA Deferred Tax Assets

Deferred Tax Assets at other companies

Zymeworks logo
ZymeworksZYME
$3.83M-20.5%
AbbVie logo
AbbVieABBV
$137M-94.7%
TG Therapeutics logo
TG TherapeuticsTGTX
$344.14M
Abbott logo
AbbottABT
$7.51B-7.5%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$81.4M-24.1%
Haemonetics logo
HaemoneticsHAE
$38.05M-39.2%

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's deferred tax assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's deferred tax assets?
ADMA Biologics (ADMA) reported deferred tax assets of $69.97M in Q1 2026.
How has ADMA Biologics's deferred tax assets changed year-over-year?
ADMA Biologics's deferred tax assets decreased by 13.5% year-over-year, from $80.86M to $69.97M.
What does deferred tax assets mean?
Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.